
Publication date:	2001-07-19	1		US7008641 (B2)
Inventor:	FAOUR JOAQUINA (AR); VERGEZ JUAN A (AR)			US6572890 (B2)
Applicant:	PHOENIX U S A INC LAB (US); FAOUR JOAQUINA (AR); VERGEZ JUAN A (AR)			US2003219483 (A1 US2001048943 (A1 CA2396156 (A1)
Classification:			ш	0/12030 100 (A1)
- international:	A61K9/00; A61K31/135; A61K31/505; A61K9/00; A61K31/135; A61K31/505; (IPC1-7): A61K9/48; A61K9/20; A61K9/22; A61K9/24; A61K9/28; A61K9/5	2;	Cited	documents:
	A61K9/58	ļ	Ų.	US6147072
- european:	A61K9/00L4; A61K31/135; A61K31/505		٦	US6096742
Application number:	WO2001US00580 20010108			US6060642
Priority number(s):	US20000175822P 20000113; US20000728276 20001130			

Report a data error here

Also published as:

Abstract of WO0151041

Patent number:

WO0151041

The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-psychotic agent in a rapid release external coat. A wide range of anti-psychotic agents can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather compression-coated onto the device. The device with spray-coated external core is smaller and easier to swallow than the similar device having a compression-coated external coat. The device is useful for the treatment of depression anxiety or psychosis related disorders.

Data supplied from the **esp@cenet** database - Worldwide